Comment · Mon, September 16, 2019 · Natrium Health & Nootropics Depot
Neuralstem stock now worth ~1/100 of that before announcing NSI-189 MDD efficiency 'failure'
Original post in this thread
ranza · 8 points
I just checked and it totally shocked me.
It looks like the hopes have been high, but it really takes a long time to deliver the product.
Previously they've stated that:
> [ NSI-189] .. did not meet its primary efficacy endpoint of a statistically significant reduction in depression symptoms on the Montgomery-Asberg Depression Rating Scale (MADRS)
However, given an over one standard deviation improvement in memory with high confidence and other (quite big improvements) (wikipedia):
> Of particular note are improvements in memory (effect size Cohen's d = 1.12, p = 0.002), working memory (d = 0.81, p = 0.020), and executive functioning (d = 0.66, p = 0.048) as measured by the CogScreen computerized test.
I find it very weird that they didn't yet commercialize the product for any other (say, nootropic) purpose.
What do you think is happening?
What they were answering
amemento · 1 points
You're right, it's a pity that such a promising drug like NSI-189 with scientific evidence of it working and a whole lot of andecdotal one, will be just lost due to incompetence on the business and marketing part. When does their patent expire? Any chance of another company using it? The latest study on it working on Angelman syndrome was very promising, too - https://www.ncbi.nlm.nih.gov/m/pubmed/30408487/
u/MisterYouAreSoDumb · Natrium Health & Nootropics Depot
They will probably sell off their IP individually once they finally admit Neuralstem's days are over and nobody is coming to buy them outright. I would imagine some company would buy the patent to NSI-189 if the price was right, and develop it for a more limited purpose.